Cargando…

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

OBJECTIVE: To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monotherapy in treatment-naïve patients with type 2 diabetes mellitus (T2DM) in China. METHODS: The Cardiff Diabetes Model, an economic model designed to evaluate the cost-effectiveness of comparator therapie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Shuyan, Mu, Yiming, Zhai, Suodi, Zeng, Yuhang, Zhen, Xuemei, Dong, Hengjin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091768/ https://www.ncbi.nlm.nih.gov/pubmed/27806087 http://dx.doi.org/10.1371/journal.pone.0165629

Ejemplares similares

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2015)

Cognitive and physical function of people older than 80 years in China from 1998 to 2014
por: Hu, Xiaoqian, et al.
Publicado: (2018)

Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2022)

Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats
por: Zhang, Minchun, et al.
Publicado: (2019)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
por: Hou, Xingyun, et al.
Publicado: (2019)

The Quality of Caregivers for the Elderly in Long-Term Care Institutions in Zhejiang Province, China
por: Zeng, Yuhang, et al.
Publicado: (2019)

Osteoarthritis in the Middle-Aged and Elderly in China: Prevalence and Influencing Factors
por: Sun, Xueshan, et al.
Publicado: (2019)

Clinical and Economic Burden of Carbapenem-Resistant Infection or Colonization Caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: A Multicenter Study in China
por: Zhen, Xuemei, et al.
Publicado: (2020)

Economic burden of antibiotic resistance in China: a national level estimate for inpatients
por: Zhen, Xuemei, et al.
Publicado: (2021)

Correction to: Economic burden of antibiotic resistance in China: a national level estimate for inpatients
por: Zhen, Xuemei, et al.
Publicado: (2021)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
por: Men, Peng, et al.
Publicado: (2020)

Modeling the Cost-effectiveness of Esophageal Cancer Screening in China
por: Li, Yuanyuan, et al.
Publicado: (2020)

Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis
por: Sun, Xueshan, et al.
Publicado: (2021)

Outpatient health-seeking behavior of residents in Zhejiang and Qinghai Province, China
por: Huang, Minzhuo, et al.
Publicado: (2019)

Measurement and analysis of equity in health: a case study conducted in Zhejiang Province, China
por: Sun, Xueshan, et al.
Publicado: (2018)

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
por: Kaku, Kohei, et al.
Publicado: (2014)

Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
por: Philip, Elizabeth, et al.
Publicado: (2013)

Acarbose is again on the stage
por: Altay, Mustafa
Publicado: (2022)

Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis
por: Gu, Shuyan, et al.
Publicado: (2020)

Trends in Cognitive Function Among Chinese Elderly From 1998 to 2018: An Age-Period-Cohort Analysis
por: Hu, Xiaoqian, et al.
Publicado: (2021)

Trends in activities of daily living disability among Chinese older adults from 1998 to 2018: an age-period-cohort analysis
por: Hu, Xiaoqian, et al.
Publicado: (2022)

Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
por: Vega-Hernandez, Gabriela, et al.
Publicado: (2017)

A comparative study of catastrophic health expenditure in Zhejiang and Qinghai province, China
por: Zhen, Xuemei, et al.
Publicado: (2018)

Chinese Minority Perceives the Doctor-Patient Relationship Differently: A Cultural and Economic Interpretation
por: Yang, Qian, et al.
Publicado: (2019)

Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients
por: He, Ke, et al.
Publicado: (2014)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2022)

Effect of multiple drug resistance on total medical costs among patients with intra-abdominal infections in China
por: Zhen, Xuemei, et al.
Publicado: (2018)

Social Determinants of Health-Related Quality of Life among Residents in Zhejiang and Qinghai, China
por: Gu, Yuxuan, et al.
Publicado: (2019)

Clinical and economic impact of methicillin-resistant Staphylococcus aureus: a multicentre study in China
por: Zhen, Xuemei, et al.
Publicado: (2020)

Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes mellitus patients in China
por: Zhang, Rong, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
por: Rosak, Christoph, et al.
Publicado: (2012)

Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes
por: Chin, Ken Lee, et al.
Publicado: (2019)

Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose
por: Huang, Jie, et al.
Publicado: (2020)

Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
por: Feng, Miao, et al.
Publicado: (2019)

On the potential of acarbose to reduce cardiovascular disease
por: Standl, Eberhard, et al.
Publicado: (2014)

Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose
por: Chen, Po-Hsun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nbfakks2kdfenj5ui9gi78qq8u